Stem Cell and Transplantation Biology

干细胞和移植生物学

• 批准号: 10207251
• 负责人: BEVERLY J. TOROK-STORB
• 金额: $ 42.48万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10207251
• 关键词: Address; Adherence; Advisory Committees; Animal Model; Area; Award; Biological Assay; Biological Products; Biology; Biomedical Research; CD34 gene; Canis familiaris; Cells; Charge; Chimerism; Collaborations; Communities; Consultations; Country; Development; Direct Costs; Disease model; Doctor of Philosophy; Dog Diseases; Educational workshop; Ensure; Faculty; Fee-for-Service Plans; Fred Hutchinson Cancer Research Center; Funding; Gene Expression; Gene-Modified; Genes; Goals; Grant; Hematological Disease; Hematology; Hematopoiesis; Human; In Vitro; Income; Individual; Institution; Internships; Liquid substance; Logistics; Measurement; Measures; Mediating; Modeling; National Institute of Diabetes and Digestive and Kidney Diseases; Nature; Nitrogen; Non-Malignant; Patients; Pilot Projects; Positioning Attribute; Pre-Clinical Model; Procedures; Process; Production; Protocols documentation; Pyruvate Kinase; Quality Control; Research; Research Personnel; Resources; Science; Services; Shipping; Ships; Site; Speed; Spumavirus; Stem cell transplant; Training; Transplantation; Travel; Underrepresented Populations; Underrepresented Students; Underserved Population; Universities; Viral; Washington; Work; Xenograft procedure; base; cost; cost effective; data sharing; design; experience; gene therapy; genetic manipulation; graft vs host disease; in vivo; in vivo Model; in vivo evaluation; member; new technology; novel therapeutics; online community; organizational structure; outcome prediction; pre-clinical; prevent; programs; quality assurance; ranpirnase; recruit; safety outcomes; stem; stem cells; tool; transplant model; transplantation therapy; treatment response; virtual; web site

PROJECT SUMMARY/ABSTRACT - Overall The theme of this CCEH is focused on stem cell and transplantation biology. The aims are designed to overcome obstacles that prevent new investigators from joining this field. Specifically the four cores will provide investigators access to: Large numbers of human and canine stem/progenitor cells; Scalable viral production services for AAV, gamma-, lenti- and foamy viruses; Products for precision gene editing and functional genetic manipulation; PCR assays for tracking chimerism, and insertion sites; Xenografting to assess human hematopoiesis; Large animal model for preclinical in vivo testing and disease modeling. The major goal of this CCEH is to make these services available throughout the US. For this purpose, products and services must be cost- effective and of high quality. Also training in best practices for the use of these resources is imperative. Towards this goal core staff provide on-site training: funds to support travel to attend training sessions are available. In addition, standard operating procedures (SOP) and quality control measures (QC) for all processes and products are shared on our website where they can be discussed and amended as the science evolves. The logistics of distributing products throughout the country are challenging. However, since the first iteration of this grant (P30 DK056465) in 1999 we have successfully shipped highly purified CD34 cells in liquid nitrogen to hundreds of satisfied investigators. Our costs are generally less than 1/3 of the cheapest commercial vender, and our product is better. Logistics for shipping other biological products to out of state users are already in place. The fees for service charged by this CCEH generates program income of $1-2 million per year. These funds are used to increase staff, develop new technologies and to fund the Enrichment Program. The goal is to help build a strong, diverse, interactive hematology research community. Included in this effort is a research internship program for students from underrepresented or underserved populations. The Seattle CCEH research base consists of 25 faculty members at the University of Washington and/or the Fred Hutchinson Cancer Research Center. Currently our research base brings in $17,130,946 in direct costs per year for studies in non-malignant hematopoiesis.

项目概要/摘要 - 总体 本届 CCEH 的主题集中在干细胞和移植生物学。其目标旨在 克服阻碍新研究者加入该领域的障碍。具体来说，四个核心将 为研究人员提供： 大量人类和犬类干/祖细胞；可扩展的病毒式传播 AAV、伽马病毒、慢病毒和泡沫病毒的生产服务；用于精确基因编辑和 功能性基因操作；用于追踪嵌合状态和插入位点的 PCR 测定；异种移植到 评估人体造血功能；用于临床前体内测试和疾病建模的大型动物模型。 该 CCEH 的主要目标是在美国各地提供这些服务。为此， 产品和服务必须具有成本效益且高质量。还提供使用最佳实践的培训 这些资源的利用势在必行。为了实现这一目标，核心员工提供现场培训：资金支持差旅 可以参加培训课程。此外，标准操作程序（SOP）和质量 所有流程和产品的控制措施（QC）均在我们的网站上共享，您可以在其中查看 随着科学的发展进行讨论和修改。 在全国范围内分销产品的物流具有挑战性。然而，自从第一次 1999 年，在这项资助 (P30 DK056465) 的迭代中，我们已成功地将高度纯化的 CD34 细胞运送到 液氮让数百名满意的研究人员满意。我们的成本一般不到最便宜的1/3 商业供应商，我们的产品更好。将其他生物制品运送到州外的物流 用户已经就位。 该 CCEH 收取的服务费每年可产生 1-200 万美元的计划收入。这些资金 用于增加员工、开发新技术和资助浓缩计划。目标是 帮助建立一个强大的、多样化的、互动的血液学研究社区。这项工作包括一项研究 针对代表性不足或服务不足人群的学生的实习计划。 西雅图 CCEH 研究基地由 25 名来自华盛顿大学和/或 弗雷德·哈钦森癌症研究中心。目前我们的研究基地带来的直接成本为 17,130,946 美元 每年用于非恶性造血研究。